

SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma

Authors: Constantine S. Tam,¹ Paolo Ghia,^{2,3} Mazyar Shadman,^{4,5} Talha Munir,⁶ Stephen S. Opat,⁷ Patricia A. Walker,⁸ Masa Lasica,⁹ Ian W. Flinn,¹⁰ Tian Tian,¹¹ Stephanie Agresti,¹¹ Jamie Hirata,¹¹ Jennifer R. Brown¹²

Affiliations: ¹Alfred Hospital and Monash University, Melbourne, VIC, Australia; ²Università Vita-Salute San Raffaele, Milano, Italy; ³IRCCS Ospedale San Raffaele, Milano, Italy; ⁴Fred Hutchinson Cancer Center, Seattle, WA, USA; ⁵University of Washington, Seattle, WA, USA; ⁶Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁷Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; ⁸Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia; ⁹St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; ¹⁰Tennessee Oncology/OneOncology, Nashville, TN, USA; ¹¹BeOne Medicines Ltd, San Carlos, CA, USA; ¹²Dana-Farber Cancer Institute, Boston, MA, USA

ABSTRACT

Background: Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor that is approved for five indications, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Initial results from the SEQUOIA study (NCT03336333), at a median follow-up of 26.2 months, demonstrated superior progression-free survival (PFS) by independent review with zanubrutinib vs bendamustine + rituximab (arms A and B) in patients with treatment-naïve (TN) CLL/SLL without del(17p) as well as high overall response rate (ORR) and PFS benefit in patients with del(17p) (arm C). Additionally, the 5-year follow-up in arm A demonstrated durable PFS benefit, with estimated 54- and 60-month PFS rates of 80% and 76%, respectively. Here we report updated results in SEQUOIA arm C, in patients with del(17p), after approximately 5 years of follow-up (data cutoff: Apr 30, 2024).

Methods: Arm C is a nonrandomized cohort of SEQUOIA patients with del(17p) that received zanubrutinib monotherapy. Investigator-assessed PFS, overall survival (OS), ORR, and safety/tolerability were evaluated. Adverse events were recorded until disease progression or start of next-line therapy.

Results: Between Feb 2018 and Mar 2019, 111 TN patients with del(17p) were enrolled to receive zanubrutinib. The median age was 71 years (range, 42-87), 79 (71%) were male, 67 (60%) were IGHV unmutated, and 47 (42%) had both del(17p) and *TP53* mutation. At a median follow-up of 65.8 months (range, 5-75), median PFS was not reached. The estimated 60-month PFS rate was 72.2% (62.4%-79.8%), or

73.0% (63.3%-80.6%) when adjusted for COVID-19. Median OS was also not reached. The estimated 60-month OS rate was 85.1% (76.9%-90.6%), or 87.0% (79.0%-92.1%) when adjusted for COVID-19. The ORR was 97.3%, and the complete response/complete response with incomplete hematologic recovery rate was 18.2%. Zanubrutinib treatment was ongoing in 62.2% of patients. The most common causes for treatment discontinuation were adverse events and progressive disease (in 17.1% and 15.3%, respectively). Key adverse events of interest (AEI) included any-grade infection (82%), bleeding (60%), neutropenia (19%), hypertension (18%), anemia (9%), thrombocytopenia (8%), and atrial fibrillation/flutter (7%). Grade ≥ 3 AEI included infection (33%), neutropenia (16%), hypertension (8%), bleeding (6%), atrial fibrillation/flutter (5%), and thrombocytopenia (2%).

Conclusions: With this 5-year follow-up in SEQUOIA, the efficacy of zanubrutinib in TN higher-risk patients with del(17p) was maintained and patients continue to demonstrate PFS benefits consistent with the randomized cohort of patients without del(17p) (arm A). Additionally, with longer-term follow-up, no new safety signals were identified. This update, in the largest cohort of uniformly treated patients with del(17p), suggests that zanubrutinib remains a valuable frontline treatment option for patients with or without del(17p) CLL/SLL. Updated data from a more recent data cut-off will be available for the presentation.